Gandhar Oil Refinery (India) Q3 FY25 consolidated revenues reaches Rs. 1,005.3 Cr
Consolidated manufacturing volumes for Q3 FY25 remained stable at 132,187 KL, while for 9M FY25 it stood at 372,505 KL
Consolidated manufacturing volumes for Q3 FY25 remained stable at 132,187 KL, while for 9M FY25 it stood at 372,505 KL
Susvimo is the first and only continuous delivery treatment that offers an alternative to regular eye injections to treat diabetic macular edema (DME)
The company will showcase groundbreaking innovations from its Pharma and Nutrition divisions, highlighting key ingredients and formulations designed to support holistic well-being
The company is committed to revolutionizing API development by advancing synthesis and analytical processes that enhance quality and impact lives
The Union Budget 2025-26 strengthens India's healthcare sector with an allocation of Rs. 99,858.56 crore, marking a 9.78% rise from Rs. 90,958.63 crore in 2024-25
The company remains focused on strengthening its direct retail presence and expanding its reach to more customers across India.
The camp, operational daily from 12 PM to 4 PM, offers free health check-ups, blood pressure monitoring
The company said it voluntarily paused production at the Gagillapur plant in September 2024 for risk assessment on account of the USFDA observations
Q3 FY25 revenue up 24% to Rs 3,230 crore
Expand the scope of the Production-Linked Incentive (PLI) scheme and increase its allocation to cover more pharmaceutical products and raw materials
Subscribe To Our Newsletter & Stay Updated